Panacea Biotec has been granted a patent by the government of India for the invention of 'Extended Release (ER) Pharmaceutical Composition Containing Nimesulide for 20 years in accordance with the provisions of the Patents Act, 1970.According to a release issued by Panacea to the BSE today, Nimesulide is one of the most widely prescribed non-steroidal, anti-inflammatory drug (NSAID) with excellent analgesic, anripyretic and safety profile. "The company launched its extended release Nimesulide under the brand name WILLGO in 2004 in India. WILLGO has recorded a growth rate of around 48% over last year," the release added.Rajesh Jain, joint managing director of the company, said: "The recent grant of patent for `Extended Release Nimesulide (WILLGO) hs greatly boosted our morale to keep up efforts in developing novel & innovative drug delivery systems through our R&D efforts. WILLGO provides effective management of Osteoarthritis by providing continuous relief from chronic joint pain in osteoarthritis patients. We have already received patent in 10 countries so far, out of 34 countries, where applications have been flied."
